Faculty

Back to Index
Jing Cui, DSc, DABR
Assistant Professor of Clinical Radiation Oncology
Radiation Oncology
GNH 1100 N. State Street Health Sciences Campus Los Angeles
+1 323 409 1383

Publications

Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr; 11(4):1036-47. View in: PubMed

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 2007 May 1; 67(9):4408-17. View in: PubMed

In vivo models of proliferative vitreoretinopathy. Nat Protoc. 2007; 2(1):67-77. View in: PubMed

A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res. 2003 Nov 1; 63(21):7345-55. View in: PubMed

Novel pyrrolyllactone and pyrrolyllactam indolinones as potent cyclin-dependent kinase 2 inhibitors. Bioorg Med Chem Lett. 2003 Jun 2; 13(11):1939-42. View in: PubMed

A novel class of tests for the detection of mitochondrial DNA-mutation involvement in diseases. Am J Hum Genet. 2003 Jun; 72(6):1515-26. View in: PubMed

Non-covalent thrombin inhibitors featuring P3-heterocycles with P1-bicyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Oct 21; 12(20):2925-30. View in: PubMed

Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. Bioorg Med Chem Lett. 2002 Apr 22; 12(8):1203-8. View in: PubMed

Powered bySC CTSI